news

ELRIG and British Pharmacological Society enter collaborative alliance

3
SHARES

Posted: 7 January 2020 | | No comments yet

The two organisations have entered into a two-year alliance to improve scientific exchange in the drug discovery industry.

The European Laboratory Research & Innovation Group (ELRIG) UK and the British Pharmacological Society have announced that they have formed a strategic alliance. The two-year agreement offers the organisations the opportunity to benefit from their respective scientific communities to help strengthen their positions and reach.

Members of ELRIG UK and the British Pharmacological Society will gain access to new openings for scientific exchange and collaboration between industry, academia and the clinic to help drive the successful discovery and development of new medicines across the UK.

Steve Rees, Chairman of ELRIG UK and VP of Discovery Biology at AstraZeneca, said: “The strategic alliance with the British Pharmacological Society formalises a joint goal of growth in the industrial and academic segments and recognises the harmonies between our organisations. Joining forces will help us improve education, networking and other services available to our communities, allowing us to become more impactful advocates for the life sciences industry.”

Members… will gain access to new openings for scientific exchange and collaboration between industry, academia and the clinic”

The alliance creates a framework for joint working on a variety of activities that will support both communities, encouraging a multidisciplinary approach that better facilitates the exchange of ideas and information. ELRIG UK and the British Pharmacological Society have committed to hosting joint and complementary meetings. It also offers both groups a wider reach, to help grow their audiences and create exciting new opportunities for early career professionals’ education and training.

Professor Steve Hill, President of the British Pharmacological Society and Professor of Molecular Pharmacology at the University of Nottingham, added: “We recognise that modern drug discovery is a multi-stakeholder process and that professionals are likely to move between sectors throughout the course of their working lives. It therefore makes sense for our programmes to represent all facets of drug discovery and we look forward to working with ELRIG UK to help achieve this goal.”

Send this to a friend